Clinical Trials Browser

Stomach Neoplasms

Advanced Biliary Tract Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Esophageal Neoplasms

Esophageal Squamour Cell Cancer

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Liver Neoplasms

Locally Advanced Rectal Cancer

Colonic Neoplasms

Advanced Gastric Cancer

Gallbladder Neoplasms, Cholangiocarcinoma

Stomach Neoplasms

Cholangiocarcinoma

Pancreatic Neoplasms

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

Stomach Neoplasms

Gastric Cancer Adenocarcinoma Metastatic

Carcinoma, Hepatocellular

Liver Neoplasms

Stomach Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Liver Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Unresectable Gallbladder Cancer

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Borderline Resectable Pancreatic Cancer

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

Rectal Neoplasms

Neoplasm Metastasis, Stomach Neoplasms

Biliary Tract Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Stomach Diseases, Stomach Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Stomach Neoplasms

Cholangiocarcinoma

Carcinoma, Hepatocellular

Second Line Treatment of Gastric Cancer

Esophageal Squamous Cell Carcinoma

Locally Advanced Gastric Cancer

Clinical Trials

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

FAD-HCC-001

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

LEAF-02

TASK-05

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

FOBECAMS

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

CAPT

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer